| Vivos Therapeutics, Inc. (VVOS) | |||||||||||||||||||||||||||||||||||||||||||||||||
| Q4-CY2025 | Q3-CY2025 | Q2-CY2025 | Q1-CY2025 | Q4-CY2024 | Q3-CY2024 | Q2-CY2024 | Q1-CY2024 | Q4-CY2023 | Q3-CY2023 | Q2-CY2023 | Q1-CY2023 | Q4-CY2022 | Q3-CY2022 | Q2-CY2022 | Q1-CY2022 | Q4-CY2021 | Q3-CY2021 | Q2-CY2021 | Q1-CY2021 | Q4-CY2020 | Q3-CY2020 | Q2-CY2020 | Q1-CY2020 | Q4-CY2019 | Q3-CY2019 | Q2-CY2019 | Q1-CY2019 | Q4-CY2018 | Q3-CY2018 | Q2-CY2018 | Q1-CY2018 | Q4-CY2017 | Q3-CY2017 | Q2-CY2017 | Q1-CY2017 | Q4-CY2016 | Q3-CY2016 | Q2-CY2016 | Q1-CY2016 | Q4-CY2015 | Q3-CY2015 | Q2-CY2015 | Q1-CY2015 | Q4-CY2014 | Q3-CY2014 | Q2-CY2014 | Q1-CY2014 | Q4-CY2013 | |
| Balance Sheet Date | 2025-Sep-30 | 2025-Jun-30 | 2025-Mar-31 | 2024-Dec-31 | 2024-Sep-30 | 2024-Jun-30 | 2024-Mar-31 | 2023-Dec-31 | 2021-Mar-31 | 2020-Dec-31 | |||||||||||||||||||||||||||||||||||||||
| Fiscal Period | Q3-FY2025 | Q2-FY2025 | Q1-FY2025 | Q4-FY2024 | Q3-FY2024 | Q2-FY2024 | Q1-FY2024 | Q4-FY2023 | Q1-FY2021 | Q4-FY2020 | |||||||||||||||||||||||||||||||||||||||
| Operating Cash Flow | (4,161,000$) | (3,494,000$) | (3,796,000$) | (2,940,000$) | (4,187,000$) | (3,048,000$) | (2,516,000$) | (2,748,000$) | (2,800,000$) | (2,859,000$) | (3,539,000$) | (3,860,937$) | (436,910$) | ||||||||||||||||||||||||||||||||||||
| Investing Cash Flow | 83,000$ | (5,906,000$) | (122,000$) | (165,000$) | (192,000$) | (60,000$) | (151,000$) | (165,000$) | (154,000$) | (245,000$) | (289,000$) | (261,703$) | (5,204$) | ||||||||||||||||||||||||||||||||||||
| Purchases of Property and Equipment | (83,000$) | 771,000$ | 122,000$ | 165,000$ | 192,000$ | 60,000$ | 151,000$ | 165,000$ | 154,000$ | 245,000$ | 239,000$ | 261,703$ | 5,204$ | ||||||||||||||||||||||||||||||||||||
| Financing Cash Flow | 2,763,000$ | 3,054,000$ | 3,787,000$ | 7,400,000$ | 3,635,000$ | 3,568,000$ | 0$ | 0$ | 7,355,000$ | (25,000$) | 79,515$ | ||||||||||||||||||||||||||||||||||||||
| End Cash Position | 3,087,000$ | 4,402,000$ | 2,342,000$ | 6,260,000$ | 6,311,000$ | 6,903,000$ | 2,611,000$ | 1,643,000$ | 3,519,000$ | 14,058,028$ | 18,205,668$ | 469,353$ | |||||||||||||||||||||||||||||||||||||
| Exchange Rate Effect | |||||||||||||||||||||||||||||||||||||||||||||||||
| Dividends Paid | |||||||||||||||||||||||||||||||||||||||||||||||||
| Unlevered Free Cash Flow | (4,078,000$) | (4,265,000$) | (3,918,000$) | (3,105,000$) | (4,379,000$) | (3,108,000$) | (2,667,000$) | (2,913,000$) | (2,954,000$) | (3,104,000$) | (3,778,000$) | (4,122,640$) | (442,114$) | ||||||||||||||||||||||||||||||||||||